October « 2014 « Science and Enterprise

Cancer Therapy Biotech Raises $24M in Early Funding

By Alan, on October 14th, 2014%

(Andrew Magill/Flickr)

14 October 2014. Raze Therapeutics, a biotechnology company designing cancer therapies that stop mechanisms feeding the growth of cancer cells, raised $24 million in its first round of venture financing. The funding round was led Atlas Venture — that co-founded Raze and provided some of its seed capital — as well . . . → Read More: Cancer Therapy Biotech Raises $24M in Early Funding

Experimental Drug Kills Myeloma Cells in Lab, Trial Planned

By Alan, on October 13th, 2014%

Guido Franzoso (Imperial College London)

13 October 2014. Medical researchers at Imperial College London in the U.K. developed an experimental drug that in lab and animal tests kills multiple myeloma cancer cells without the toxic side effects of other cancer drugs. The team led by Imperial medical professor Guido Franzoso published its findings today . . . → Read More: Experimental Drug Kills Myeloma Cells in Lab, Trial Planned

New Coating Material Stops Blood Clots, Bacterial Films

By Alan, on October 13th, 2014%

These glass slides were dipped in blood to demonstrate the effectiveness of the tethered–liquid perfluorocarbon or TLP coating. While blood sticks to the untreated slide on the left, the slide treated with TLP on the right emerges entirely clear. (Wyss Institute, Harvard University)

13 October 2014. Engineers and medical researchers at Harvard University developed . . . → Read More: New Coating Material Stops Blood Clots, Bacterial Films

Hepatitis C Combination Drug Approved by FDA

By Alan, on October 10th, 2014%

Microscopic view of the hepatitis C virus (VA.gov)

Updated 11 October 2014. The U.S. Food and Drug Administration approved a drug combining a new compound, ledipasvir, with the existing drug sofosbuvir to treat hepatitis C genotype 1, the most common form of the disease. The combination of ledipasvir and sofosbuvir is developed and . . . → Read More: Hepatitis C Combination Drug Approved by FDA

Stem Cells Engineered to Produce Insulin-Making Cells

By Alan, on October 9th, 2014%

Human stem cell derived beta cells in mice (Doug Melton, Harvard University)

9 October 2014. Researchers at Harvard University developed a technique that enables embryonic stem cells to transform into large quantities of insulin-producing beta cells found in the pancreas, a key step in developing a treatment for type 1 diabetes. The team . . . → Read More: Stem Cells Engineered to Produce Insulin-Making Cells

Mind-Controlled Prosthetic Arm Given Long-Term Test

By Alan, on October 9th, 2014%

The recipient of the prosthetic arm works in a demanding job, as a truck driver (Chalmers University of Technology)

9 October 2014. Biomedical engineers in Sweden developed and tested for 18 months a prosthetic device connected to a man’s amputated arm that provides electrical signaling with his mind and body. The team of . . . → Read More: Mind-Controlled Prosthetic Arm Given Long-Term Test

Patent Awarded for Detailed Pandemic Flu Detection Test

By Alan, on October 8th, 2014%

U.S. Patent and Trademark Office (A. Kotok)

8 October 2014. A genomics-based test to detect various types of pandemic influenza, including mutated forms resistant to antiviral drugs, is the recipient of a recent patent. The U.S. Patent and Trademark Office awarded patent number 8,808,993 — Methods and Kits to Detect New H1N1 “Swine . . . → Read More: Patent Awarded for Detailed Pandemic Flu Detection Test

Drug Screening Target Designed for All Ebola Types

By Alan, on October 8th, 2014%

Scanning electron micrograph of Ebola virus (National Institute of Allergy and Infectious Diseases)

8 October 2014. Researchers at University of Utah and Navigen Inc., both in Salt Lake City, designed a synthetic peptide acting like a protein found in all strains of the Ebola virus that can serve as a target when screening . . . → Read More: Drug Screening Target Designed for All Ebola Types

Company Launched for Tissue Regrowth, Inflammation Drugs

By Alan, on October 7th, 2014%

Eva Turley (London Health Sciences Centre)

7 October 2014. Novare Pharmaceuticals, an enterprise commercializing research on a protein that can treat inflammatory diseases and help create new cells for rebuilding tissue, such as after a mastectomy, began operations today under the auspices of Allied Minds, a company creating start-ups based on scientific discoveries at . . . → Read More: Company Launched for Tissue Regrowth, Inflammation Drugs

Genes Identified to Boost Vitamin A in Corn

By Alan, on October 6th, 2014%

Orange corn, naturally high in carotenoids (Natalie van Hoose, Purdue University)

6 October 2014. Agricultural researchers at Purdue University identified a few key genes that can increase ingredients in corn for building vitamin A in humans. And because these genes are already found in some corn varieties, say the authors, new types of . . . → Read More: Genes Identified to Boost Vitamin A in Corn

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise